Biomea Fusion Stock (NASDAQ:BMEA)

Forecast Revenue Ownership Financials Chart

Previous Close

$4.27

52W Range

$3.61 - $20.21

50D Avg

$5.34

200D Avg

$7.74

Market Cap

$154.74M

Avg Vol (3M)

$906.56K

Beta

-0.43

Div Yield

BMEA Company Profile

Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

107

IPO Date

Apr 16, 2021

Website

BMEA Performance

BMEA Financial Summary

	Dec 23	Dec 22	Dec 21
Revenue	-	-	-
Operating Income	$-126.14M	$-83.63M	$-41.67M
Net Income	$-117.25M	$-80.02M	$-41.22M
EBITDA	$-121.93M	$-83.63M	$-41.67M
Basic EPS	$-3.44	$-2.73	$-1.73
Diluted EPS	$-3.44	$-2.73	$-1.73

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison

Ticker	Company
DSGN	Design Therapeutics, Inc.
HOWL	Werewolf Therapeutics, Inc.
EWTX	Edgewise Therapeutics, Inc.
CGEM	Cullinan Oncology, Inc.
IKNA	Ikena Oncology, Inc.